METTL3 and METTL14 knockdown or FTO overexpression favors tumor progression in glioblastoma due to altered m6A levels in the target gene, ADAM metalloproteinase domain 19 (ADAM19).[31] A contrasting finding, also reported by Li et al., showed that FTO‐mediated demethylation of the target oncogenic mRNA transcripts results in poor differentiation of AML cells leading to oncogenic cell transformation and leukemogenesis. The gene discussed is FTO; the disease is glioblastoma.